Abstract
The Forkhead transcription factor FOXO3a has emerged as a versatile target for diseases that impact upon neuronal survival, vascular integrity, immune function, and cellular metabolism. Enthusiasm is high to fill a critical treatment void through FOXO3a signaling for several neurodegenerative disorders that include aging, neuromuscular disease, systemic lupus erythematosus, stroke, and diabetic complications. Here we discuss the influence of FOXO3a upon cell survival and longevity, the intricate signal transduction pathways of FOXO3a, insights into present disease models, and the potential clinical translation of FOXO3a signaling into novel therapeutic strategies.
Keywords: Amyotrophic lateral sclerosis, diabetes, apoptosis, FOXO3a, FKHRL1, Akt, erythropoietin, neuromuscular disease, oxidative stress, psychiatric
Current Neurovascular Research
Title: “SLY AS A FOXO”: New Paths with Forkhead Signaling in the Brain
Volume: 4 Issue: 4
Author(s): Kenneth Maiese, Zhao Zhong Chong and Yan Chen Shang
Affiliation:
Keywords: Amyotrophic lateral sclerosis, diabetes, apoptosis, FOXO3a, FKHRL1, Akt, erythropoietin, neuromuscular disease, oxidative stress, psychiatric
Abstract: The Forkhead transcription factor FOXO3a has emerged as a versatile target for diseases that impact upon neuronal survival, vascular integrity, immune function, and cellular metabolism. Enthusiasm is high to fill a critical treatment void through FOXO3a signaling for several neurodegenerative disorders that include aging, neuromuscular disease, systemic lupus erythematosus, stroke, and diabetic complications. Here we discuss the influence of FOXO3a upon cell survival and longevity, the intricate signal transduction pathways of FOXO3a, insights into present disease models, and the potential clinical translation of FOXO3a signaling into novel therapeutic strategies.
Export Options
About this article
Cite this article as:
Maiese Kenneth, Chong Zhong Zhao and Shang Chen Yan, “SLY AS A FOXO”: New Paths with Forkhead Signaling in the Brain, Current Neurovascular Research 2007; 4 (4) . https://dx.doi.org/10.2174/156720207782446306
DOI https://dx.doi.org/10.2174/156720207782446306 |
Print ISSN 1567-2026 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5739 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Vitamin D Supplementation in Diabetic Foot Ulcers: A Current Perspective
Current Diabetes Reviews Consequences of Iron Accumulation in Microglia and its Implications in Neuropathological Conditions
CNS & Neurological Disorders - Drug Targets Glutamate Receptors in Human Caudate Nucleus in Normal Aging and Alzheimer’s Disease
Current Alzheimer Research Editorial [Hot Topic: Regulation of Glutamate Synthesis Via Inhibition of Glutamate Carboxypeptidase II (GCPII): An Effective Method to Treat Central and Peripheral Nervous System Disorders (Guest Editors: Guido Cavaletti and Barbara Slusher)]
Current Medicinal Chemistry Editorial: The New Trial EMPAREG-OUTCOMES in Type 2 Diabetes: “and Death Shall Have no Dominion”?
Current Vascular Pharmacology Editorial [Hot Topic:Role of Neural Stem Cells in Neurodegenerative Diseases:From the Molecule and Cell to the Clinic (Guest Editor: Oscar Gonzalez-Perez)]
Current Signal Transduction Therapy Oxidative Status in Multiple Sclerosis and Off-Targets of Antioxidants: The Case of Edaravone
Current Medicinal Chemistry Meet Our Editorial Board Member
Current Alzheimer Research Endotherapia
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Neuroprotective Effects of Tetracyclines: Molecular Targets, Animal Models and Human Disease
CNS & Neurological Disorders - Drug Targets Resolvins: Endogenously-Generated Potent Painkilling Substances and their Therapeutic Perspectives
Current Neuropharmacology Therapeutic Approaches for Lysosomal Storage Diseases: A Patent Update
Recent Patents on CNS Drug Discovery (Discontinued) Identification of Pharmacological Targets in Amyotrophic Lateral Sclerosis Through Genomic Analysis of Deregulated Genes and Pathways
Current Genomics Meet Our Editorial Board Member
Current Neuropharmacology A New Interpretative Paradigm for Conformational Protein Diseases
Current Protein & Peptide Science Dynamic Expression of MicroRNAs (183, 135a, 125b, 128, 30c and 27a) in the Rat Pilocarpine Model and Temporal Lobe Epilepsy Patients
CNS & Neurological Disorders - Drug Targets Inflammasome as a New Therapeutic Target for Diabetic Complications
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Platelet-Activating Factor (PAF) Antagonists Attenuate Inflammatory- Based Pain: Potential Cellular and Anatomical Sites of PAF Action
Central Nervous System Agents in Medicinal Chemistry Mechanisms Involved in the Genesis of Diabetic Nephropathy
Current Diabetes Reviews Heat Shock Proteins: Therapeutic Drug Targets for Chronic Neurodegeneration?
Current Pharmaceutical Biotechnology